Open forum infectious diseases · 2026
Osteoarticular Coccidioidomycosis in California: A Single-Center Experience.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Arya Radhika, Dzinoreva Melissa, Shiu Traci, Thottacherry Elizabeth, Chang Amy, Aronson Jenny, Kappagoda Shanthi, Furukawa Daisuke
Аннотация
BACKGROUND: Osteoarticular involvement in coccidioidomycosis is an uncommon manifestation leading to significant morbidity, but evidence surrounding it is limited. We aimed to describe the clinical characteristics of osteoarticular coccidioidomycosis and identify factors associated with treatment failure.
METHODS: We performed a retrospective chart review of adults age ≥18 years hospitalized with confirmed osteoarticular coccidioidomycosis at an academic tertiary care center between 2004 and 2021. We extracted demographic, clinical, microbiologic, treatment, and outcomes data. Univariable regression analysis was used to identify risk factors of disease progression or relapse.
RESULTS: Thirty-two patients were reviewed, of whom 29 (91%) were male, with a median age (interquartile range [IQR]) of 46.8 (35.1-65.6) years and a median time of follow-up (IQR) of 84 (47-127) months. The most common sites of infection were spine (n = 15, 47%) and knee (n = 9, 28%). Itraconazole was the most common antifungal used (n = 16, 50%), followed by posaconazole (n = 8, 25%), and surgery was performed in 24 (75%) patients. The median treatment duration (IQR) was 45.0 (13.3-66.7) months, with 26 (81%) patients remaining on antifungals through the last day of follow-up. Fifteen (47%) patients experienced progression and/or relapse. Knee (odds ratio [OR], 18.29; 95% CI, 91-175.35) and multisite infections (OR, 6.56; 95% CI, 1.10-39.32) were associated with disease progression and/or relapse, while spine infection was associated with lower rates of progression and/or relapse (OR, 0.20; 95% CI, 0.44-0.90).
CONCLUSIONS: Patients with osteoarticular coccidioidomycosis required prolonged therapy with a substantial risk of disease progression or relapse. Knee and multisite infections were associated with poorer outcomes. Larger studies are needed to validate these findings and optimize treatment strategies.
METHODS: We performed a retrospective chart review of adults age ≥18 years hospitalized with confirmed osteoarticular coccidioidomycosis at an academic tertiary care center between 2004 and 2021. We extracted demographic, clinical, microbiologic, treatment, and outcomes data. Univariable regression analysis was used to identify risk factors of disease progression or relapse.
RESULTS: Thirty-two patients were reviewed, of whom 29 (91%) were male, with a median age (interquartile range [IQR]) of 46.8 (35.1-65.6) years and a median time of follow-up (IQR) of 84 (47-127) months. The most common sites of infection were spine (n = 15, 47%) and knee (n = 9, 28%). Itraconazole was the most common antifungal used (n = 16, 50%), followed by posaconazole (n = 8, 25%), and surgery was performed in 24 (75%) patients. The median treatment duration (IQR) was 45.0 (13.3-66.7) months, with 26 (81%) patients remaining on antifungals through the last day of follow-up. Fifteen (47%) patients experienced progression and/or relapse. Knee (odds ratio [OR], 18.29; 95% CI, 91-175.35) and multisite infections (OR, 6.56; 95% CI, 1.10-39.32) were associated with disease progression and/or relapse, while spine infection was associated with lower rates of progression and/or relapse (OR, 0.20; 95% CI, 0.44-0.90).
CONCLUSIONS: Patients with osteoarticular coccidioidomycosis required prolonged therapy with a substantial risk of disease progression or relapse. Knee and multisite infections were associated with poorer outcomes. Larger studies are needed to validate these findings and optimize treatment strategies.